Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Savara IncSVRA · Entity 4900 | Director | February 16, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Savara Inc
Report date February 16, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,644 |
Reported balance
After 2026-02-16 transaction · row 1
1 source rowRow 1 · 2026-02-16 · Exercise / conversion · Acquired 1,807 · Balance 302,644 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.76 · Expires 2026-12-15 | Direct | 0 |
Reported balance
After 2026-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-16 · Exercise / conversion · Disposed 1,807 · Balance 0 F1: The shares subject to the option vested and became exercisable in twelve equal quarterly installments beginning on March 15, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vested and became exercisable in twelve equal quarterly installments beginning on March 15, 2017.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kindred Biosciences, Inc.
Report date August 27, 2021 · Filed August 30, 2021
Section 16 reporting ended · disclosed 2021-08-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.65 · Expires 2028-04-19 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-27 · Disposition to issuer · Disposed 41,890 · Balance 0 F1: This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2028-06-21 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-27 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.91 · Expires 2029-01-31 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-27 · Disposition to issuer · Disposed 48,500 · Balance 0 F3: This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.84 · Expires 2030-01-16 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-27 · Disposition to issuer · Disposed 48,500 · Balance 0 F4: This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-01-19 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-27 · Disposition to issuer · Disposed 48,500 · Balance 0 F5: This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $233,285.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for no consideration.
F2: This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F3: This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F4: This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F5: This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $233,285.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
LUMOS PHARMA, INC.
Report date December 12, 2024 · Filed December 13, 2024
Section 16 reporting ended · disclosed 2024-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 1
1 source rowRow 1 · 2024-12-12 · Disposition to issuer · Disposed 15,721 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) $4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2033-05-09 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-12 · Disposition to issuer · Disposed 3,345 · Balance 0 F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2034-06-04 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-12 · Disposition to issuer · Disposed 3,328 · Balance 0 F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2030-04-02 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-12 · Disposition to issuer · Disposed 5,684 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.18 · Expires 2032-05-04 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-12-12 · Disposition to issuer · Disposed 3,431 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.36 · Expires 2031-05-19 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-12-12 · Disposition to issuer · Disposed 2,910 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) $4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.
F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option.
F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement.
Nexvet Biopharma plc
Report date July 31, 2017 · Filed August 02, 2017
Section 16 reporting ended · disclosed 2017-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 1
1 source rowRow 1 · 2017-07-31 · Disposition to issuer · Disposed 16,400 · Balance 0 F1: Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2017 Filed Jul 5, 2017 12:59 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionOrdinary Shares | 3,600 | $0.13 | $450.00 |
DisclosureSEC source: 0001171000-17-000047 · edgar.xml · nonDerivative · entry 2 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 12:59 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionRestricted Share Units · Derivative | 500 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001171000-17-000047 · edgar.xml · derivative · entry 3 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 500 shares Expires 2019-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 12:59 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionOrdinary Shares | 500 | $0.13 | $62.50 |
DisclosureSEC source: 0001171000-17-000047 · edgar.xml · nonDerivative · entry 1 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 14:30 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 52,250 | $4.75 | $248,187.50 |
DisclosureSEC source: 0000899243-17-015868 · doc4.xml · nonDerivative · entry 1 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,866 Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 11:23 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionRestricted Share Units · Derivative | 500 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001572426-17-000013 · edgar.xml · derivative · entry 2 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Ordinary Shares · 500 shares Expires 2019-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 500 of the Restricted Share Units vested and became convertible on 3/31/17, and 500 Restricted Share Units shall vest and become convertible on 6/30/17, subject to payment of the nominal value per share to Issuer within 30 days of vesting. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 11:23 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionOrdinary Shares | 500 | $0.13 | $62.50 |
DisclosureSEC source: 0001572426-17-000013 · edgar.xml · nonDerivative · entry 1 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 19:38 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionRestricted Share Units · Derivative | 500 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001572426-17-000006 · edgar.xml · derivative · entry 2 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Ordinary Shares · 500 shares Expires 2019-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 500 of the Restricted Share Units vested and became convertible on 12/31/16, and 500 Restricted Share Units shall vest and become convertible on each of 3/31/17 and 6/30/17, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting. Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 19:38 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionOrdinary Shares | 500 | $0.13 | $62.50 |
DisclosureSEC source: 0001572426-17-000006 · edgar.xml · nonDerivative · entry 1 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 15:52 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionRestricted Share Units · Derivative | 500 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001572426-16-000238 · edgar.xml · derivative · entry 2 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Ordinary Shares · 500 shares Expires 2019-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 500 of the Restricted Share Units vested and became convertible on 9/30/16, and 500 Restricted Share Units shall vest and become convertible on each of 12/31/16, 3/31/17 and 6/30/17, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 15:52 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionOrdinary Shares | 500 | $0.13 | $62.50 |
DisclosureSEC source: 0001572426-16-000238 · edgar.xml · nonDerivative · entry 1 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2016 Filed Sep 7, 2016 17:49 UTC | Nexvet Biopharma plc NVET · Entity 174046 | Exercise / conversionRestricted Share Units · Derivative | 3,600 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001572426-16-000230 · edgar.xml · derivative · entry 1 McCracken Joseph S · CIK 0001632454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Ordinary Shares · 3,600 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 3,600 of the Restricted Share Units shall vest and become convertible on 7/1/17, subject to payment of the nominal value per share to Issuer within 30 days of vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.